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Systemic pharmacological inhibition of nitric oxide (NO) causes a hypertensive response,
which has been attributed both to inhibition of peripheral NO-mediated vasodilatation
and to inhibition of central nervous NO-production leading to a later onset sympathetic
vasoconstriction. In the present study we aimed to test the importance of these two
mechanisms by comparing the time-courses of the hypertensive responses in spinal
cord injured (SCI) subjects with varying degrees of loss of sympathetic vascular control
depending on level of injury as well as able-bodied controls. We hypothesized that
high level SCI with no sympathetic vasoconstrictor control would have an abbreviated
time-course of the hypertensive response to the NO-inhibitor L-NAME, because they
would lack the late onset sympathetic component to the hypertensive response. NO
production was blocked in 12 subjects with SCI and 6 controls by intravenous infusion
of L-NAME (1.55–2.7mg/kg). We measured blood pressure, heart rate, and vascular
conductance in the carotid, brachial, and femoral arteries before, during, and after 1 h
of L-NAME in a 4-h protocol. Peak increases in mean arterial pressure were significantly
larger in high level SCI vs. controls: 32 ± 6 vs. 12 ± 2mmHg (both groups received
1.55mg/kg). The decreases in vascular conductance in the brachial and femoral vascular
beds were also larger in the high level SCI group, whereas decreases in heart rate and
carotid conductance were not significantly different between the groups. There were no
indications of any abbreviated responses in blood pressure or vascular conductance in
the high level SCI compared to control. The mid level and low-level SCI subject had
responses similar to controls. These data confirm previous reports that NO inhibition
causes a larger increase in blood pressure in high level SCI, and extend these data by
providing evidence for differences in vascular conductance in the limbs. The current
data do not support an obligatory important role for sympathetic vasoconstriction in
maintaining the hypertensive response to L-NAME in humans.
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INTRODUCTION
Resting blood pressure (BP) is brought about by a combination
of cardiac output and peripheral resistance. The primary
determinant of peripheral resistance is the internal diameter of
the arterioles in the muscle and splanchnic vascular beds, which
is controlled on a beat-to-beat basis by reflex vasoconstriction
governed by the arterial baroreflex. Flow-mediated dilatation
(FMD), which is largelymediated by nitric oxide (NO), is brought
about by the shear stress of blood flow through resistance vessels
and counteracts this vasoconstriction (Raitakari and Celermajer,
2000; Mullen et al., 2001; Patel and Celermajer, 2006; Kooijman
et al., 2008). Of course, it is now known that the elusive
endothelium-derived relaxing factor (EDRF) is in fact nitric
oxide (NO), which acts directly on local smooth muscle and
relaxes it (Palmer et al., 1987).
An increasing body of literature has demonstrated that NO is
of functional importance for vasodilation and the normal control
of BP in animals (Cunha et al., 1993; Sander et al., 1995, 1997), as
well as in humans (Calver et al., 1992; Vallance et al., 1992; Sander
et al., 1999; Young et al., 2009). Indeed, blocking nitric oxide
synthase (NOS) by nitro-L-arginine methyl ester (L-NAME) in
young normotensive individuals can cause arterial pressure to
increase by on average 24mmHg (Sander et al., 1999).
Previous studies in both animals and humans have indicated
that NO inhibition causes an increase in blood pressure through
inhibition of endothelium dependent vasodilation as well as
central disinhibition of the sympathetic nervous vasoconstrictor
tone (Cunha et al., 1993; Sander et al., 1995, 1997, 1999). The
latter mechanism would then be caused by NO inhibition within
the central nervous system, specifically in some of the brainstem
centers involved in the central baroreflex signaling and in the
brainstem centers involved in the central sympathetic outflow.
While the peripheral mechanism is initiated as soon as NO
inhibition begins, the central sympathetic activation caused by
NO inhibition seems slower in onset, and may be delayed by 1–
2 h after initiation of systemic NO inhibition (Sander et al., 1999).
In a specific rat model of high spinal cord injury, previous studies
have suggested that SCI rats have a lower hypertensive response
to NO inhibition than controls (Sakuma et al., 1992; Togashi
et al., 1992).
In the present study we aimed to test whether loss of
sympathetic vasoconstrictor tone would change the magnitude
or the time-course of the hypertensive response to NO
inhibition in humans. We hypothesized that loss of sympathetic
vasoconstriction in high-level spinal cord injured (SCI) patients
would shorten the time-course of the hypertensive response to
L-NAME.
Given that resting BP is often low in SCI, and more so in high-
level SCI because of interruption of descending vasoconstrictor
drive, one might have expected that NO production would be
lower because of reduced perfusion pressure and shear stress
through the resistance vessels. However, a recent study revealed
that L-NAME caused a higher increase in blood pressure in high-
level SCI individuals compared to controls (Wecht et al., 2007,
2008). This means that in high level SCI there is an increased NO
production playing a greater role in resting blood pressure, either
through increased basal NO production or due to the peripheral
NO effects being unopposed by sympathetic vasoconstriction.
Indeed, it has been shown that in patients with autonomic
failure in whom there is no sympathetic output, blocking NO
production also increases blood pressure more so than in healthy
controls (Gamboa et al., 2008).
The present study was initiated in 2005 and we recruited
patients and controls until 2008. At this point the above data
from Wecht and colleagues was published, and the similar time-
courses for the blood pressure responses in high level SCI and
in controls they observed strongly suggested that there would
be no discernible abbreviation of the hypertensive response
to L-NAME in SCI patients with little or no sympathetic
vasoconstrictor drive.
The current study confirms the conclusions reached byWecht
et al. (2007, 2008), but extends it in the following ways: (i) we
compared the hemodynamic responses to L-NAME infusion in
high-, mid-, and low-level SCI patients and able-bodied controls,
and (ii) we used Doppler ultrasound to measure blood flow and




Studies were performed on 12 individuals with complete or
incomplete (AIS B) SCI. One individual with high level SCI
did not complete the protocol, due to headache in conjunction
with a high blood pressure increase during L-NAME infusion.
In this individual the L-NAME-infusion was stopped prior to
end-point of the protocol and L-Arginine was given to revert the
blood pressure raising effect of NO-inhibition. This individual
was subsequently fine, but only a limited dataset from this trial
was included in the analysis. We included a full dataset from
the remaining 11 individuals with SCI. The SCI patients had
suffered their injury 11 months-33 years previously and ranged
in age from 22 to 63 years (mean ± SE − 42 ± 3 years).
We recruited six healthy controls (26–63; 42 ± 5 years). All
subjects were male with the exception of one SCI and one control
subject.
We specifically wanted to address whether SCI lesion level
(and thus the residual central sympathetic control) affected the
magnitude and the time-course of the changes in BP, heart rate,
and blood flow during blockade of NO production. Accordingly,
data from groups of four high-level (C5-T2), four mid-level (T4-
T6), and four low-level (T7-T10) SCI individuals were compared
to the control group. These groups of SCI subjects, separated
according to level of lesion, and the control subjects are shown
in Table 1.
Subjects with a history of cardiovascular disease, diabetes,
hypertension, or other co-morbidity were excluded from the
study. The SCI subjects continued their normal medication, none
of which are known to interfere with the cardiovascular system.
All participating subjects gave written (or oral and witnessed)
informed consent, and the study received ethical approval from
theHuman Research Ethics Committees of the University of New
South Wales and Prince of Wales Hospital.
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TABLE 1 | Subject characteristics and baseline vs. peak blood pressure and heart rate.
Subject characteristics Baseline vs. peak response
Systolic Diastolic Heart rate
Age LEVEL AIS TSI mmHg bpm
38* C5/C6 B 20y 2m 104 172 60 101 60 37
45 C5/C6 B 8y 8m 114 153 62 81 46 31
40 C5/C6 B 1y 2m 81 129 44 67 45 31
38 T2 A 5y 105 175 61 97 68 35
22 T4 A 11m 106 144 55 77 57 41
39 T4 A 6y 104 138 57 77 49 34
33 T4 A 8y 10m 113 139 57 77 63 41
37 T6 A 19y 10m 130 164 71 93 47 41
57 T7 A 32y 8m 141 161 78 95 48 39
32 T7 B 5y 3m 103 127 49 64 64 50
49 T8 A 6y 5m 135 171 82 103 72 51
63 T10 A 29y 126 153 72 89 53 43
32* HC 105 115 62 76 76 56
44 HC 140 155 85 81 59 41
37 HC 117 131 64 85 56 48
26 HC 105 118 55 74 55 41
47 HC 135 155 84 94 58 46
63 HC 129 162 78 93 51 41
AIS, American Spinal Injury Association (ASIA) Impairment Scale; TSI, time since injury; HC, healthy control. The * indicates the subject is a female.
Procedure and Analysis
All subjects were studied in the morning after an overnight fast,
resting in a semi-reclined position with the room at a comfortable
ambient temperature. The female SCI subject did remain in her
motorized wheelchair for testing, but the wheelchair could be
reclined so she was in the same position as the other subjects.
All subjects emptied their bladder before the procedure, and
those SCI subjects with an indwelling catheter were monitored
throughout to ensure there were no drainage problems that could
interfere with their BP.
Blood pressure was monitored non-invasively, using
oscillometric arm cuff measurements, and radial artery
tonometry (CBM-7000, Colin Corp., Japan). Heart rate (HR)
was measured via standard Ag-AgCl ECG surface electrodes on
the chest. Each BP and heart rate measurement was averaged
over 5min (typically 5 blood pressure measurements and
heart rate averaged over 5min). In the right common carotid,
brachial, and femoral arteries ultrasound 2D-images of vascular
diameter (in perpendicular long axis views, the calculated mean
diameters were 2/3 diastolic diameter + 1/3 systolic diameter)
and Doppler-derived mean blood velocities (automated mean
blood velocity detection over 3–5 heart beats in steady state)
were obtained with a 11 MHz linear-array vascular transducer
(SonoSite Titan; Bothell, WA, USA). Flow was calculated as
vascular cross-sectional area times mean blood velocity and
conductance as flow divided by mean arterial pressure.
A 20 gauge intravenous cannula was inserted into the median
cubital vein for infusion of (L-NAME) or L-arginine (a substrate
for NO synthesis). After recording baseline measurements of BP,
HR, and vascular conductances, L-NAME was administered over
60min. After the early experience with a high blood pressure
response in a patient with high-level SCI, the L-NAME dosing
was adjusted such that patients with high-level SCI received
1.55mg/kg, the remainder of the SCI patients (mid and low)
received 2.7mg/kg. Of the control subjects 4 were matched for
gender and age with the high level SCI patients (see Table 1) and
received 1.55mg/kg and the last 2 controls received 2.7mg/kg.
This approach allowed for direct comparison of the responses
in high-level SCI and controls with the comparison between
all groups being performed by normalizing to the administered
L-NAME dose (responses/mg of L-NAME/kg body weight). At
the completion of the L-NAME-infusion, there were 120min of
additional recordings. After a total of 180min (L-NAME infusion
for 60min and 120min of follow-up) L-arginine, 200mg/kg, was
administered intravenously over 15–20min.
In addition to baseline measures, BP, HR, flow, and
conductance measurements were obtained at 30, 60, 90, 120,
150, 180, and 210min. BP and HR were also measured at 15
and 45min. The 210-min measurements represent the response
to L-arginine. These time points were compared to baseline
with regards to absolute values, and percentage changes from
baseline were compared between groups. In the figures, values are
presented as mean± SE. For each parameter, we used a one-way,
repeated-measures, ANOVA within the group, and a two-factor
ANOVA with repeated measures on one factor (time) between
the groups (Prism 6 for Mac, GraphPad Software Inc., USA).
Differences were considered statistically significant at p < 0.05
with Dunn’s correction for multiple comparisons.
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RESULTS
Hemodynamic Effects of NO-Inhibition
with L-NAME in Three Patients with
High-Level SCI and Four Age and Gender
Matched Able-Bodied Controls
Intravenous infusion of L-NAME (1.55mg/kg) caused increases
in arterial pressures, decreases in heart rate in all SCI and control
subjects. Figure 1 depicts the absolute values for the changes in
systolic, mean and diastolic blood pressures and heart rates in
the group of high-level SCI patients and the matched controls.
The increases in all pressures were 2–3 times higher in the SCI
patients compared to the controls: the largest systolic pressure
increase in SCI vs. controls: 47± 14 vs. 13± 1mmHg [F(1, 45) =
79.39; p < 0.0001]; the largest mean arterial pressure increase
in SCI vs. controls: 32 ± 6 vs. 12 ± 2mmHg [F(1, 45) = 54.83;
p < 0.0001]; the largest diastolic blood pressure increase in SCI
vs. controls: 24 ± 6 vs. 12 ± 2mmHg [F(1, 45) = 26.65; p <
0.0001]. The differences in blood pressures at baseline, with the
high-level SCI group starting much lower than the control group,
were completely evened out after L-NAME. Despite the large
differences in blood pressure responses, the heart rate changes
were not significantly different between the groups: the largest
decrease in SCI vs. controls was −19 ± 5 vs. −15 ± 2 bpm
[F(1, 45) = 8.707; p = 0.005]. When normalized to the increases
in blood pressure, HR decreased by −0.8 and −1.6 bpm/mmHg
in the high-level SCI and control groups, respectively; there was
no significant difference in these falls in HR.
The average diameters of the common carotid, brachial, and
femoral arteries (all three are conduit arteries) before and during
L-NAME were not significantly changed in either group. There
were some expected differences in absolute diameter between the
groups, since the high level SCI group had substantially smaller
femoral artery diameter (5.5 ± 0.4mm) compared to the control
group (8.2± 1.2mm), whereas the brachial and carotid diameters
were similar between the groups. The actual values before and
during L-NAME for all groups (also the mid level and the low
level SCI groups) are shown in Table 2.
The fact that diameter of these conduit arteries do not change
during NO blockade means the changes in flow are related
to changes in perfusion pressure and degree of downstream
vasoconstriction. Vascular conductance measurements accounts
for the changes in perfusion pressure in a linear fashion, and
Figure 2 depicts the relative changes in conductance in the three
vascular beds in the SCI and control groups.
Flow in the common carotid artery was not significantly
changed in either group but carotid vascular conductance was
decreased in both groups: change from baseline in SCI vs.
controls: −38 ± 6 vs. −32 ± 4% [F(1, 35) = 3.501; p = 0.0697].
Flow in the brachial artery was higher at baseline in high-
level SCI compared to control, and the decrease was large and
significant whereas there was no significant change in the control
group: −35 ± 8 vs. −4 ± 15%. Brachial vascular conductance
also changed markedly in high-level SCI but not significantly in
controls: −55 ± 7 vs. −16 ± 12% [F(1, 35) = 42.72; p < 0.0001].
In the femoral artery data showed decreases in blood flow: SCI vs.
FIGURE 1 | Absolute changes (±SE) from baseline for systolic (top
panel), mean (2nd panel), and diastolic (3rd panel) blood pressures (in
mmHg); and heart rate (bottom panel) (BPM), during L-NAME, post
L-NAME, and post L-arginine infusions in high-level SCI patients (black
triangles) and matched controls (white circles). Time 0 is baseline
measurements, the 15–60min time points represent the L-NAME infusion,
90–180min is post L-NAME infusion, and the 210min time point represents
post L-arginine infusion. For all variables L-NAME caused a significant change
in both groups. There was a group effect for all blood pressure changes, such
that the high-level SCI patients had larger increases in blood pressures
compared to controls, whereas there was no group effect in the heart rate
responses. There was insufficient power to test differences at specific
time-points. We could find no indication of a differing time-course for the
L-NAME effect in high-level SCI compared to controls.
controls: −46 ± 6 vs. −24 ± 6%; and in vascular conductance:
SCI vs. controls: −62 ± 7 vs. −34 ± 5% [F(1, 35) = 22.90;
p < 0.0001], a clear tendency for larger relative decreases in SCI
compared to controls.
Hemodynamic Effects of NO-Inhibition
with L-NAME in High, Mid, and Low Level
SCI and Able Bodied Controls
The effects of intravenous infusion of L-NAME (1.55–2.7mg/kg)
in the three patient groups and the control group were compared
by normalizing to the L-NAME dose. Figure 3 depicts the
absolute changes in systolic, mean and diastolic blood pressures
and heart rates normalized to L-NAME dose in the four groups.
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TABLE 2 | Carotid, brachial, and femoral diameters at baseline and after the full L-NAME dose had been administered.
Carotid diameter Brachial diameter Femoral diameter
Baseline L-NAME Baseline L-NAME Baseline L-NAME
High SCI 5.7± 0.3 6.1± 0.2 4.4±0.3 4.3±0.4 5.4±0.3 5.5±0.4
Mid SCI 6.3± 0.04 6.2± 0.1 4.4±0.3 4.4±0.3 5.8±0.3 5.8±0.3
Low SCI 6.6± 0.4 6.5± 0.5 5.0±0.2 4.9±0.2 6.2±0.2 6.2±0.2
Controls 6.1± 0.2 6.1± 0.2 4.3±0.3 4.3±0.3 9.0±0.8 9.0±0.8
The data for all four groups show that the diameters in these conductance vessels do not change when a NOS inhibitor is used to increase peripheral resistance.
FIGURE 2 | Percentage changes (±SE) from baseline for carotid (top
panel), brachial (middle panel), and femoral conductances, during
L-NAME, post L-NAME, and post L-arginine infusions in high-level SCI
patients (black triangles) and matched controls (white circles). Time 0 is
baseline measurements, the 30–60min time points represent the L-NAME
infusion, 90–180min is post L-NAME infusion, and the 210min time point
represents post L-arginine infusion. L-NAME caused large decreases in
carotid, brachial, and femoral conductances in high-level SCI patients,
whereas the L-NAME effects reached significance in the carotid conductance
in controls. There were significantly higher decreases in conductance in the
brachial and femoral conductances in the high-level SCI patients compared to
matched controls.
These data clearly demonstrates that the high-level SCI group
differs from themid- and low-level SCI groups as well as controls.
Roughly the blood pressure responses normalized to L-NAME
dose are 2–3 times higher in the high-level SCI group compared
to all three other groups. Heart rate decreases also tended to be
larger in the high-level SCI group.
Figure 4 depicts the relative changes in conductance in the
three vascular beds, normalized to L-NAME dose, in all four
groups. Again the high-level SCI subjects had larger decreases
in brachial and femoral flow and conductance compared
to controls. The mid-level SCI patients had very similar
decreases in femoral conductance to the high level SCI patients,
whereas the low-level SCI patients had decreases in femoral
conductance that were similar to controls. However, there was
no statistically significant difference between the changes in flow
and conductances.
L-Arginine Caused Reversal of all
Hemodynamic Effects of L-NAME in all
Individuals
As seen in Figures 1–4, there was reversal of the L-NAME
effects in all groups with regards to all hemodynamic variables
measured. This underscores the point that the L-NAME effects
are most likely primarily—or exclusively—related to inhibition
of NOS.
DISCUSSION
We have confirmed that systemic NO-inhibition in high-level
SCI patients causes a significantly higher increase in blood
pressure compared to matched control and compared to
mid- and low-level SCI patients. Conversely, the bradycardic
responses were not significantly different, suggesting the
baroreflex-induced vagally-mediated bradycardia is intact in all
groups. We have extended this finding by providing data that
the relative decreases in vascular conductances in the brachial,
and the femoral arteries are large in high level SCI. Although
the decrease in femoral conductance in mid-level SCI is similar
to high-level SCI, the blood pressure responses were different,
suggesting that decreases in vascular conductance in the renal
and splanchnic beds must be larger in high level SCI than in any
of the other groups.
We set out to test the underlying mechanisms for the
L-NAME induced increases in blood pressure by studying
patients with SCI at different levels. In previous animal and
human studies, evidence has been presented for a dominating
peripheral mechanism where L-NAME blocks endothelially-
derived vasodilatation, and a late-onset smaller effect of
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FIGURE 3 | All data are normalized to an L-NAME dose of 1mg/kg.
Absolute changes from baseline (±SE) for systolic (top panel), mean (2nd
panel), and diastolic (3rd panel) blood pressures (in mmHg); and heart rate
(bottom panel) (BPM), during L-NAME, post L-NAME, and post L-arginine
infusions in high-level SCI patients (black triangles), mid-level SCI patients
(black squares), low-level SCI patients (black diamonds), and matched
controls (white circles). Time 0 is baseline measurements, the 15–60min time
points represent the L-NAME infusion, 90–180min is post L-NAME infusion,
and the 210min time point represents post L-arginine infusion. For all variables
L-NAME caused a significant change in all groups. There was a group effect
for all blood pressure changes, such that the high-level SCI patients had larger
increases in blood pressures compared to the other three groups, whereas
there was no group effect in the heart rate responses. There was insufficient
power to test differences at specific time-points.
central sympathetic activation (Sander et al., 1997, 1999). The
significance of such a late-onset sympathetic component has been
unclear, although previous human studies suggested it could
be responsible for as much as one third of the total response
during the third hour after onset of NO-inhibition (Sander et al.,
1999). The rationale in the present study was that, the higher
the SCI level the smaller this late-onset sympathetically-mediated
effect would be, since the sympathetic effector nerves are without
central control below the level of the lesion (if the lesion is
complete). During the latter part of our study period, Wecht
et al. (2008) published data on the L-NAME induced hypertensive
FIGURE 4 | All data are normalized to an L-NAME dose of 1mg/kg.
Percentage changes (±SE) from baseline for carotid (top panel), brachial
(middle panel), and femoral conductances, during L-NAME, post L-NAME,
and post L-arginine infusions in high-level SCI patients (black triangles),
mid-level SCI patients (black squares), low-level SCI patients (black diamonds),
and matched controls (white circles). Time 0 is baseline measurements, the
30–60min time points represent the L-NAME infusion, 90–180min is post
L-NAME infusion, and the 210min time point represents post L-arginine
infusion. L-NAME caused large decreases in carotid, brachial, and femoral
conductances in high-level SCI patients and significant changes also occurred
for the other three groups. There were no statistically significant differences
between the groups.
responses in SCI patients vs. controls. In their study, which
showed a higher blood pressure increase in high level SCI patient,
there were no discernible differences in the time-courses of the
blood pressure responses between SCI and controls. Our data
confirm this, as we found a higher increase in blood pressure
in high-level SCI patients compared to controls and to mid-
and low-level SCI patients. However, we found no suggestion
of an abbreviated blood pressure response in high-level SCI,
which would be expected if a late-onset central sympathetically
mediated component was important. This underscores that NOs
role in the control of vascular resistance is important, and that
blocking this peripheral mechanism seems the more important
factor in the hypertensive response to NO-inhibition.
What then is the explanation for the heightened blood
pressure response in high-level SCI patients? A priori, we
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can think of two likely possibilities: (1) high-level SCI has
a higher peripheral NO production leading to a higher NO-
mediated vasodilation, which when blocked causes a higher
increase in total peripheral resistance and hence blood pressure;
(2) in subjects with an intact sympathetic nervous system,
the L-NAME-induced increase in blood pressure leads to a
baroreflex-mediated withdrawal of sympathetic vasoconstriction
which buffers the increase in blood pressure, and in high-
level SCI, this buffering is absent, because the sympathetic
vasoconstrictor drive is absent due to the SCI.
We know that following SCI there is vascular remodeling,
such that the luminal diameters of the carotid and femoral
arteries are reduced (de Groot et al., 2006; Thijssen et al., 2008,
2012). Our data confirms that SCI patients have reduced diameter
in the femoral arteries (Table 2). It seems, the explanation for
this remodeling is primarily related to lack of muscle use, since
patients with all levels of SCI (all in wheel chairs) have decreased
femoral artery diameters, even though only high- and mid-
level SCI have lack of sympathetic activation in the legs. In a
previous study, Thijssen et al. (2008) have calculated that mean
wall shear stress in a femoral conduit artery is about 30% higher
in SCI compared to controls. If the decreased diameter of the
conduit arteries is a good indicator for shear stress at the level
of the resistance vessels and hence the shear stress induced
NO production, it would be expected that all SCI groups had
similar changes in femoral conductance. However, the high-
level SCI had a larger L-NAME-induced decrease in femoral
vascular conductance that the other two groups. Furthermore,
the vascular remodeling does not knowingly occur in the renal
arteries or the splanchnic vascular bed. These observations
collectively speak against an increased peripheral NO production
in high-level SCI compared to able-bodied controls. In a
previous study, the intra-arterial infusion of the NO inhibitor L-
monomethyl-L-arginine (L-NMMA) caused a similar decrease in
flow and conductance in SCI and controls (Bleeker et al., 2005).
Together this indicates that if differences exist for nitric oxide
production in SCI and controls, the functional significance of
such a difference seems limited.
Buffering the blood pressure raising effect of L-NAME by
withdrawal of sympathetic vasoconstrictor tone seems logical. In
this context, we would expect that in the resting human, an intact
sympathetic innervation of the splanchnic and renal vascular bed
would be paramount for such a buffering. Both the mid-level and
the low-level SCI patients in the present study would be expected
to have intact (or at least substantial) sympathetic innervation
of the renal and splanchnic vascular beds. The similar blood
pressure responses in mid- and low-level SCI and controls in the
present study are consistent with this notion. Previous studies in
humans have shown that muscle sympathetic activity is lowered
during the initial phase of NO inhibition (Hansen et al., 1994;
Lepori et al., 1999; Charkoudian et al., 2006). Recently, Wecht
et al. (2008) reported decreases in noradrenaline levels (taken
as an indirect measure of sympathetic withdrawal) in healthy
subjects after L-NAME, and this buffering mechanism was not
seen in high-level SCI patients that showed no significant changes
in noradrenaline levels after L-NAME.
The limitations of the study are primarily related to the small
number of subjects included in each group. A larger study was
not feasible, because the L-NAME formerly produced for human
use (by Clinalfa) was taken off the market around 2006. While we
had some L-NAME in stock, we did utilize it during the course of
this study, where subjects were enrolled up until 2008. We could
have gained important knowledge if we had been able to obtain
reliable data for mesenteric and renal vascular conductance, but
although we aimed at this, the data quality was only sufficient
in about 50%, and given the already small groups we elected not
include any unclear data.
In conclusion, lack of central sympathetic control in high-level
SCI does not cause changes in the time course of the hypertensive
response to L-NAME. Furthermore, we confirmed that high-level
SCI patients have a significantly more pronounced hypertensive
response compared to the mid- and low-level SCI groups as well
as controls.
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